Nobivac Intra-Trac III

Canine Adenovirus Type 2-Parainfluenza-Bordetella Bronchiseptica Vaccine.

Modified Live Virus, Avirulent Live Culture DIRECTIONS FOR USE - PLEASE READ CAREFULLY Intra-Trac 3 vaccine is recommended for use as an aid in the prevention of disease associated with canine adenovirus type 2, canine parainfluenza virus and Bordetella bronchiseptica infection in healthy dogs 3 weeks of age or older. These agents have been implicated as playing a role in the etiology of the condition known as canine kennel cough.

Nobivac: INTRA-TRAC 3INTRA-TRAC® 3 Schering-Plough Canine Adenovirus Type 2-Parainfluenza-Bordetella Bronchiseptica Vaccine Modified Live Virus, Avirulent Live Culture DIRECTIONS FOR USE - PLEASE READ CAREFULLY Intra-Trac 3 vaccine is recommended for use as an aid in the prevention of disease associated with canine adenovirus type 2, canine parainfluenza virus and Bordetella bronchiseptica infection in healthy dogs 3 weeks of age or older. These agents have been implicated as playing a role in the etiology of the condition known as canine kennel cough. PREPARATION OF THE VACCINE 1. Rehydrate live vaccine to desired volume with the accompanying Sterile Diluent.* 2. Draw the vaccine back into syringe. 3. Remove needle from syringe. 4. Apply nasal applicator tip to syringe. HOW TO VACCINATE *Standard dose is 1 mL administered intranasally. Vaccine may be rehydrated with less than 1 mL of diluent to minimize discomfort when vaccinating small dogs and puppies. For one 1 mL dose, rehydrate vaccine with 1 mL sterile diluent or for one 0.5 mL dose, rehydrate vaccine with 0.5 mL sterile diluent. Instill the rehydrated vaccine into one or both nostrils of dogs as illustrated below. WHEN TO VACCINATE Vaccinate dogs at 3 weeks of age or older. Revaccinate annually. CAUTION 1. THIS PRODUCT IS DESIGNED FOR INTRANASAL USE ONLY WITH THE ENCLOSED DILUENT. Systemic reactions resulting from inadvertent intramuscular or subcutaneous injection have been reported. Symptoms may include vomiting, diarrhea, lethargy, inappetence, jaundice and death associated with liver failure. Localized tissue necrosis at the injection site has also been reported. If inadvertent injection occurs, monitor the dog closely. Supportive therapy including IV fluids and treatment with gentamicin, tetracycline or trimethoprim/sulfa may be indicated. 2. Post-vaccinal reactions consisting of mild canine cough syndrome may occur following use of this vaccine. 3. For veterinary use only. Store at 2° to 7°C (35° to 45°F). Use entire contents when first opened. Burn this container and all unused contents. If anaphylactoid reaction occurs, use epinephrine. 4. This vaccine contains penicillin, streptomycin and nystatin as preservatives. U.S. Veterinary License No. 165A Schering-Plough Animal Health Corp., Omaha, Nebraska 68103, USA 1 800 224-5318 (USA) © Copyright 2002 Schering-Plough Animal Health Corp. All rights reserved. P13946-11 NDC 25x1 Dose Vials of Vaccine Varied Dose Volume 0061-1391-01 P13944-12 150x1 Dose Vials of Vaccine Varied Dose Volume 0061-1391-02 P13945-11 NAC No.: 10472401